The articles in this supplement are based on presentations given at a PharmaMar-sponsored satellite symposium held at the British Gynaecological Cancer Society annual scientific meeting, in July 2014 in London. The articles comprise mainly reviews of published data. They include a review of the recent stratification of the recurrent ovarian cancer population (ROC) into different, identifiable subgroups based on platinum-free interval (PFI). This stratification will help guide treatment sequencing management strategies for these different patient groups. The articles also include a discussion of PFI extension strategies through intercalation of a non-platinum combination, such as trabectedin plus pegylated liposomal doxorubicin (PLD), between platinum therapies, and the survival advantage this brings.
展开▼
